Exploration of Targeted Anti-tumor Therapy

Table 1

The clinicopathological features of HCC cases with or without po-TACE treatment

Variable	Controls (n = 160)		Po-TACEs (n = 158)		χ²	P
Variable	n	%	n	%	χ²	P
Age (years old)^a
48	91	56.9	88	55.7	0.045	0.832
> 48	69	43.1	70	44.3	0.045	0.832
Gender
Male	113	70.6	102	64.6	1.337	0.248
Female	47	29.4	56	35.4	1.337	0.248
Race
Han	93	58.1	79	50.0	2.113	0.146
Zhuang	67	41.9	79	50.0	2.113	0.146
HBV status
Negative	47	29.4	54	34.2	0.846	0.358
Positive	113	70.6	104	65.8	0.846	0.358
HCV status
Negative	146	91.3	137	86.7	1.674	0.196
Positive	14	8.8	21	13.3	1.674	0.196
Smoking status
No	121	75.6	121	76.6	0.040	0.841
Yes	39	24.4	37	23.4	0.040	0.841
Drinking status
No	113	70.6	122	77.2	1.790	0.181
Yes	47	29.4	36	22.8	1.790	0.181
AFP (ng/L)
20	57	35.6	59	37.3	0.101	0.750
> 20	103	64.4	99	62.7	0.101	0.750
Liver cirrhosis
No	37	23.1	40	25.3	0.208	0.648
Yes	123	76.9	118	74.7	0.208	0.648
ES grade^b
Low	80	50.0	88	55.7	1.036	0.309
High	80	50.0	70	44.3	1.036	0.309
MVD
No	55	34.4	56	35.4	0.040	0.842
Yes	105	65.6	102	64.6	0.040	0.842

Return to article view

^a Age is grouped according to the average age of patients with HCC (47.94 years old 9.98 years old); ^b ES grade is divided into two groups: low grade (ES-I and -II grade) and high grade (ES-III and -IV grade). AFP: α-fetoprotein